10:41 AM
 | 
Oct 19, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA accepts resubmitted BLA for ADMA's RI-002

FDA accepted for review a resubmitted BLA from ADMA Biologics Inc. (NASDAQ:ADMA) for RI-002 to treat primary immune...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >